Sanofi-Synthélabo
Welcome to MedLibrary.org. For best results, we recommend beginning with the navigation links at the top of the page, which can guide you through our collection of over 14,000 medication labels and package inserts. For additional information on other topics which are not covered by our database of medications, just enter your topic in the search box below:
 |
|
| Type | Société Anonyme |
|---|---|
| Traded as | Euronext: SAN, NYSE: SNY, LSE: 0I42, FWB: SNW |
| Industry | Pharmaceuticals |
| Founded | 20 August 2004 (by acquisition) |
| Headquarters | 54, rue La Boétie, 8th arrondissement, Paris, France |
| Key people | Chris Viehbacher (CEO), Serge Weinberg (Chairman), Jean-François Dehecq (Original Founder) |
| Products | Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...) |
| Revenue | €33.38 billion (2011)[1] |
| Operating income | €7.499 billion (2011)[1] |
| Profit | €5.693 billion (2011)[1] |
| Total assets | €100.16 billion (2011)[1] |
| Total equity | €56.38 billion (2011)[1] |
| Employees | 113,719 (2011)[1] |
| Subsidiaries | Genzyme, Sanofi Pasteur, Chattem, Shantha Biotechnics, Zentiva, Medley, Nichi-Iko, Merial |
| Website | www.sanofi.com |
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales.[2][3] Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).[4] Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[5] The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo. It changed its name to Sanofi in May 2011. In January 2012 Sanofi announced that they will invest $125 Million in Warp Drive Bio to support their cancer research program.
Contents |
History
Sanofi-Synthélabo
Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France.
Aventis
Aventis was formed in 1999 when French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.
Merger and beyond
Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 billion for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.
October 2010: Sanofi-Aventis SA laid off 1,700 US employees due to restructuring triggered by growing generic competition and other factors. The cuts were completed throughout 2011 according to transition needs. The layoffs amount to about 25 percent of the company's US pharmaceutical operation. The company denies the action was related with acquisition plan of buying US biotech firm Genzyme Corp.[6]
The company dropped the -Aventis suffix of its name on 6 May 2011 after receiving approval at its AGM. The reason given by the company for the change was to make its name easier to pronounce in countries such as China.[7]
Business
Products
- Glimepiride (Amaryl) for type 2 diabetes mellitus
- Human Insulin (Insuman) for type 1 and 2 diabetes mellitus
- Alfuzosin (Xatral) for benign prostatic hyperplasia
- Cabazitaxel (Jevtana) for prostate cancer
- Clomifene (Clomid) for Female infertility
- Clopidogrel (Plavix, Iscover) for atherothrombosis
- Codeine (Solpadol) for Chronic pain
- Docetaxel (Taxotere) for breast, lung and prostate cancer
- Enoxaparin (Lovenox, Clexane) for thrombosis (its biggest seller in 2008)[8]
- Fexofenadine (Allegra, Telfast) and Triamcinolone (Nasacort) for allergic rhinitis
- Insulin glulisine (Apidra) and Insulin glargine (Lantus) for diabetes
- Irbesartan (Aprovel, Avapro, Delix, Karvea, Triatec, Tritace) for hypertension
- Ketoprofen (Bi-profined) for pain
- Menactra for meningitis
- Oxaliplatin (Eloxatin) for colorectal cancer
- Risedronic acid (Actonel) for osteoporosis and Paget’s disease
- Valproic acid (Depakine) and Valproate semisodium (Depakote) for epilepsy
- Zolpidem (Ambien, Ambien CR, Myslee, Stilnoct, Stilnox, Zolfresh, Zolt) for insomnia
The company also produces a broad range of over-the-counter products, among them Allegra, IcyHot for muscle pain, Gold Bond for skin irritation, and Selsun Blue dandruff shampoo (these brands were acquired in 2010 when Sanofi-Aventis purchased Chattem).
Management
- Serge Weinberg, Chairman
- Chris Viehbacher, CEO[9]
- Jean-François Dehecq was the General Manager of Sanofi from its creation in 1973 until 2007.
Stockholders
As of 31 January 2011:[1]
- Breakdown of share ownership: 5.16% by Total, 9.02% by L'Oréal, 0.46% treasury shares and 1.43% employees. The remaining 83.93% are publicly traded.
- Voting rights distribution: 8.89% to Total, 15.61% to L'Oréal, 2.33% to employees, and 73.17% to the public.
Head office
In January 2012, Sanofi moved its head office location to 54, rue La Boétie in the 8th arrondissement of Paris. This former mansion designed by architect René-Patouillard had previously been the head office of Alcatel-Lucent.
Sanofi's previous head office was located in the 13th arrondissement of Paris, 174 Avenue de France. The architecture of the head office is of the predominate style of the area surrounding the François Mitterrand Library. After Sanofi and Aventis merged, the employees at the former Aventis head office in Schiltigheim, Alsace moved to Paris.[10]
Collaborative research
In addition to internal research and development activities Sanofi is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[11][12] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[13]
In June 2010, Sanofi and the Charite University of Berlin signed a cooperation agreement for the research and development of medicines and therapies.[14]
On October 25, Sanofi said its earnings for the third quarter slumped as generic competitors ate into profits of its Eloxatin cancer treatment. [15]
Aventis Foundation
The Aventis Foundation,[16] a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education and healthcare research.
See also
References
- ^ a b c d e f g "Annual Report 2010". Sanofi-Aventis. Retrieved 13 April 2011.
- ^ IMS Health 2008
- ^ Keller, Greg (10 September 2008). "Sanofi names Viehbacher as new CEO". Associated Press (USA Today). Retrieved 2009-04-19.
- ^ "Sanofi-Aventis to sign deal to build flu vaccine plant in China - source". AFX News (Forbes). 23 November 2007. Retrieved 2009-04-19.
- ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Retrieved 2008-08-25.
- ^ Sanofi-Aventis To Lay Off 1,700 US Employees http://www.cbsnews.com/stories/2010/10/08/ap/health/main6939445.shtml
- ^ Mennella, Noelle (6 May 2011). "Sanofi changes name, pace of acquisitions to slow". Reuters. Retrieved 7 May 2011.
- ^ "Annual Review 2008". Sanofi-Aventis. Retrieved 2009-04-19.
- ^ Chris Viehbacher wird Nachfolger von Sanofi-Aventis-Chef Le Fur 10.09.2008
- ^ "Sanofi-Aventis : regroupement à Paris." Le Journal du Net. Retrieved on 28 September 2010.
- ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2 [Amazon-US | Amazon-UK]. PMID 18449490.
- ^ "InnoMed PredTox Member Organizations". Retrieved 2008-08-25.
- ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved 2008-08-25.
- ^ Sanofi-aventis, Charite University Sign Cooperation Agreement News article from InfoGrok.
- ^ "Sanofi Earns Slump in Q3 as Competition Heats Up". The New York Times. October 25, 2012.
- ^ http://www.aventis-foundation.org/
